Fifth Third Bancorp Sells 3,838 Shares of Eli Lilly and Company (LLY)
Fifth Third Bancorp decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,062 shares of the company’s stock after selling 3,838 shares during the period. Fifth Third Bancorp’s holdings in Eli Lilly and were worth $9,510,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of LLY. Heritage Trust Co bought a new stake in shares of Eli Lilly and during the first quarter worth $135,000. Penserra Capital Management LLC increased its stake in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the last quarter. Crestwood Advisors Group LLC bought a new stake in shares of Eli Lilly and during the first quarter worth $179,000. Sandy Spring Bank increased its stake in shares of Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after buying an additional 750 shares during the last quarter. Finally, Coldstream Capital Management Inc. bought a new stake in shares of Eli Lilly and during the first quarter worth $200,000. 75.77% of the stock is currently owned by institutional investors.
Eli Lilly and Company (NYSE:LLY) traded up 0.13% during mid-day trading on Monday, reaching $78.89. The company had a trading volume of 416,540 shares. The firm’s 50 day moving average price is $81.83 and its 200-day moving average price is $81.93. The company has a market capitalization of $83.23 billion, a price-to-earnings ratio of 34.14 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the company posted $0.86 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.64%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.
ILLEGAL ACTIVITY WARNING: “Fifth Third Bancorp Sells 3,838 Shares of Eli Lilly and Company (LLY)” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/fifth-third-bancorp-sells-3838-shares-of-eli-lilly-and-company-lly/1528153.html.
A number of equities research analysts recently weighed in on LLY shares. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $92.00 price objective on shares of Eli Lilly and in a research report on Tuesday, May 16th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research report on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price target (up from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a research note on Tuesday, July 4th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $87.92.
In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares in the company, valued at approximately $1,134,231.98. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 669,733 shares of company stock worth $55,845,287. Corporate insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.